García-Martínez Elena, Pérez-Fidalgo J Alejandro
Department of Medical Oncology, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB), Grupo Español de Investigación en Cáncer de Ovario (GEICO), Murcia, Spain.
Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Valencia, Spain.
EJC Suppl. 2020 Aug 22;15:87-95. doi: 10.1016/j.ejcsup.2020.02.002. eCollection 2020 Aug.
Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.
卵巢癌是妇科癌症的主要死因，人们迫切期待新的治疗方法。尽管已证实肿瘤浸润淋巴细胞的存在与较好的预后相关，但免疫疗法尚未纳入卵巢癌的治疗手段中。本综述简要总结了针对三种不同类型肿瘤（免疫沙漠型、炎症型和免疫排除型卵巢肿瘤）已进行测试或正在研究的策略。最后，为成功开发新的免疫治疗策略，需要更好地了解生物学和免疫微环境。
